Trials / Active Not Recruiting
Active Not RecruitingNCT03377023
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer. Researchers also want to find out if the combination of nivolumab, ipilimumab and nintedanib is safe and tolerable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Intravenous nivolumab every 2 weeks. |
| DRUG | Ipilimumab | Intravenous ipilimumab every 6 weeks. |
| DRUG | Nintedanib | Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles. |
Timeline
- Start date
- 2018-02-02
- Primary completion
- 2023-11-28
- Completion
- 2026-08-01
- First posted
- 2017-12-19
- Last updated
- 2026-04-02
- Results posted
- 2025-03-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03377023. Inclusion in this directory is not an endorsement.